DDrare: Database of Drug Development for Rare Diseases

Searched query = "Cryopyrin-associated periodic syndrome", "Cryopyrin associated periodic fever syndrome", "Familial cold autoinflammatory syndrome", "FCAS", "Mucke-Wells syndrome", "MWS", "Chronic infantile neurologic cutaneous, and articular syndrome", "CINCA syndrome", "Neonatal onset multisystem inflammatory disease", "NOMID"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = ACZ885; ACZ885 drug substance; ATI-450; Anakinra; Anti-interleukin-1B monoclonal antibody; C-028380; CANAKINUMAB; Canakinumab; Canakinumab (ACZ885); Canakinumab (WHO approval pending); Canakinumab (company code: ACZ885D); ILARIS; IZD174; IZD334; Ilaris; Inzomelid; Kineret; Recombinant human monoclonal antibody to human IL-1Beta of the IgG1/K class; Recombinant human monoclonal antibody to human IL-1beta of the IgG1/K class; Rilonacept; Rilonacept 160 mg; Tranilast; XOMA 052

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04524858 (ClinicalTrials.gov)	October 23, 2020	19/8/2020	Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS)	A Phase 2a, Open-Label, Single-Arm Study to Investigate the Safety and Efficacy of ATI-450 for the Maintenance of Remission in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS) Previously Managed With Anti-IL-1 Therapy	Cryopyrin-Associated Periodic Syndrome	Drug: ATI-450	Aclaris Therapeutics, Inc.	NULL	Recruiting	18 Years	N/A	All	10	Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04524858
(ClinicalTrials.gov)

October 23, 2020

19/8/2020

Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS)

A Phase 2a, Open-Label, Single-Arm Study to Investigate the Safety and Efficacy of ATI-450 for the Maintenance of Remission in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS) Previously Managed With Anti-IL-1 Therapy

Cryopyrin-Associated Periodic Syndrome

Drug: ATI-450

Aclaris Therapeutics, Inc.

NULL

Recruiting

18 Years

N/A

All

Phase 2

United States